<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31475" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Zolpidem</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bouchette</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>St.Martinus Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akhondi</surname>
            <given-names>Hossein</given-names>
          </name>
          <aff>University of Nevada</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Quick</surname>
            <given-names>Judy</given-names>
          </name>
          <aff>Aurora Vista Del Mar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Bouchette declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hossein Akhondi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Judy Quick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31475.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Zolpidem&#x000a0;is a non-benzodiazepine receptor modulator that is primarily indicated for the short-term alleviation of insomnia, particularly in individuals with sleep initiation challenges. This activity&#x000a0;discusses zolpidem&#x000a0;and its effectiveness in alleviating sleep latency duration and curtailing nocturnal awakenings, especially in cases of transient insomnia. Zolpidem&#x000a0;is also used as an adjunct in augmenting sleep quality for those confronting chronic insomnia, owing to its minor muscle relaxant properties. Zolpidem's pharmacological attributes, optimal dosing considerations, adverse effects, and pertinent contraindications will also be discussed.&#x000a0;The activity&#x000a0;emphasizes interprofessional collaboration for the adept management of insomnia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for zolpidem.</p></list-item><list-item><p>Evaluate&#x000a0;the mechanism of action of zolpidem.</p></list-item><list-item><p>Assess the adverse effects of zolpidem.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from zolpidem therapy for insomnia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31475&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31475">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31475.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Zolpidem tartrate is a non-benzodiazepine receptor modulator primarily used in the FDA-approved short-term treatment of insomnia aimed at patients with difficulty falling asleep.<xref ref-type="bibr" rid="article-31475.r1">[1]</xref>&#x000a0;Zolpidem belongs to the control substance class C IV medicines and is regulated by the Drug Enforcement Agency.&#x000a0;This drug improves measures of sleep latency and sleep duration and reduces the number of awakenings in patients with transient insomnia.<xref ref-type="bibr" rid="article-31475.r2">[2]</xref>&#x000a0;Zolpidem also improves sleep quality in patients with chronic insomnia and can act as a minor muscle relaxant.<xref ref-type="bibr" rid="article-31475.r3">[3]</xref>&#x000a0;The American Society of Sleep Medicine (AASM) recommends zolpidem for sleep onset and sleep maintenance insomnia in adults.<xref ref-type="bibr" rid="article-31475.r4">[4]</xref>&#x000a0;In case the patient continues to have persistent insomnia after 7 to 10 days of zolpidem treatment, it is recommended to conduct a thorough evaluation to identify any underlying medical or psychiatric conditions.&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Research&#x000a0;has also&#x000a0;shown that zolpidem is rapid and effective in restoring brain function in patients who are in a vegetative state after brain injury. The drug has the potential to completely or partially reverse the abnormal metabolism of damaged brain cells.<xref ref-type="bibr" rid="article-31475.r5">[5]</xref>&#x000a0;Patients typically recover if the injury is in non-brain stem areas.</p>
      </sec>
      <sec id="article-31475.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Zolpidem is a non-benzodiazepine hypnotic agent that works as a gamma-aminobutyric acid (GABA), a type of receptor chloride channel modulator/agonist that increases GABA inhibitory effects leading to sedation. The GABAa receptor, also called GABA-BZ, is found in the sensorimotor cortical regions, globus pallidus, inferior colliculus, pons, ventral thalamic complex, olfactory bulb, cerebellum, and substantial in the brain. The drug upregulates these receptors, allowing for the sedative effects leading to the preservation of deep sleep.<xref ref-type="bibr" rid="article-31475.r6">[6]</xref></p>
        <p>Unlike&#x000a0;benzodiazepines, which non-selectively bind to and activate all benzodiazepine (BZ) receptor subtypes, zolpidem binds the BZ1 receptor preferentially with a high-affinity ratio of the alpha1/alpha5 subunits.<xref ref-type="bibr" rid="article-31475.r7">[7]</xref>&#x000a0;The selective binding of zolpidem on the BZ1 receptor may explain the relative absence of myorelaxant and anticonvulsant effects. Zolpidem is generally not recommended as a first-line treatment due to its misuse/abuse potential.<xref ref-type="bibr" rid="article-31475.r8">[8]</xref>.&#x000a0;Drugs like controlled-release melatonin and doxepin may&#x000a0;be used&#x000a0;as the first-line therapy in addition to&#x000a0;proper sleep hygiene and&#x000a0;cognitive behavioral therapy for patients with insomnia.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Zolpidem is swiftly absorbed from the gastrointestinal tract, whether in immediate-release or controlled-release forms. The immediate-release version achieves peak concentration (Tmax) in approximately 1.6 hours. When taken with food, immediate-release zolpidem exhibits a 15% reduction in mean AUC and a 25% decrease in Cmax. The Tmax is extended by 60% (from 1.4 to 2.2 hours), while the half-life remains unaltered. These findings suggest that, for faster sleep onset, zolpidem tartrate tablets should not be ingested with or immediately after a meal. The controlled-release formulation maintains plasma levels for over&#x000a0;3 hours post-administration. When administered as a single 12.5 mg dose, these tablets have a median Tmax of 1.5 hours. In a food-effect study involving the controlled-release tablets, food consumption&#x000a0;causes a 23% reduction in mean AUC, along with prolongation of median Tmax from 2 to 4 hours. The sublingual formulation of zolpidem tartrate disintegrates within the sublingual cavity after administration. On average, it is rapidly absorbed in both genders, with a mean Tmax ranging from about 35 minutes to 75 minutes. Zolpidem tartrate is cleared from the body at a slower rate in women than in men. Female subjects exhibit about 45% higher Cmax and AUC parameters than male subjects when administered at the same dose. Therefore, adult women require a lower initial dose of 5 mg, while adult men can take 5 mg or 10 mg.</p>
        <p><bold>Distribution:</bold> Total protein binding for both forms of zolpidem is high (92.5 &#x000b1; 0.1%).</p>
        <p><bold>Metabolism:</bold> Zolpidem undergoes primary metabolism through various enzymes, including CYP3A4, CYP2C9, CYP1A2, and CYP2D6, with CYP3A4 being particularly significant in the biotransformation. The standard and extended-release formulations are converted into inactive metabolites, primarily excreted through renal pathways.<xref ref-type="bibr" rid="article-31475.r9">[9]</xref></p>
        <p><bold>Elimination:</bold> The controlled-release formulation has a mean elimination half-life of 2.8 hours (range: 1.62 to 4.05 hr). Immediate-release tablets, at 5 mg (range: 1.4 to 4.5 hours) or 10 mg (range: 1.4 to 3.8 hours), exhibit mean elimination half-lives within this specified range. The peak serum concentration (Cmax) of sublingually administered zolpidem is typically achieved within 35 to 75 minutes, and the drug has a half-life of approximately 2.5 hours.<xref ref-type="bibr" rid="article-31475.r10">[10]</xref></p>
      </sec>
      <sec id="article-31475.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Zolpidem oral formulation is available as a tablet and an extended-release tablet.&#x000a0;Zolpidem is also available as an oral spray formulation sprayed into the mouth over the tongue and a sublingual tablet to place under the tongue. Depending on the patient's sleep quality, it is administered in 5 mg or 10 mg tablets orally. Zolpidem is then converted to an inactive metabolite and excreted by the kidneys. Tablets are not scored. Ingestion with or immediately after food intake may slow the effects of this drug.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The recommended initial dose is 5 mg for women and 5 mg or 10 mg for men, taken only once per night immediately before bedtime, with at least 7 to 8 hours remaining before the planned time of awakening. Zolpidem clearance is lower in women.<xref ref-type="bibr" rid="article-31475.r11">[11]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The dosage&#x000a0;should be changed in patients with hepatic impairment, as zolpidem's half-life was many times&#x000a0;longer than in patients with normal liver function.&#x000a0;</p>
        <p><bold>Renal impairment: </bold>Zolpidem pharmacokinetics remain consistent in renal impairment, requiring no dosage adjustment.&#x000a0;In patients undergoing hemodialysis for end-stage renal failure, there is no significant difference in key pharmacokinetic parameters for zolpidem between the initial and final administration days.&#x000a0;This&#x000a0;suggests that renal function does not notably impact zolpidem metabolism or clearance.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>As zolpidem can cross the placenta, maternal use of zolpidem in the third trimester of pregnancy or during labor could lead to respiratory depression and sedation in neonates upon birth. Therefore, it is recommended to monitor and manage neonates exposed to maternal zolpidem or during labor for signs of hypotonia, excessive sedation, and respiratory depression. However, published data from post-marketing surveillance, observational studies, case reports, and birth registries on the maternal use of zolpidem during pregnancy have not concluded a clear association between zolpidem use and significant congenital disabilities. There are limited moderate to severe cases of respiratory depression reported after birth in neonates who require intratracheal intubation or artificial ventilation. However, once treated, most of these neonates recovered within hours to a few weeks after birth.<xref ref-type="bibr" rid="article-31475.r12">[12]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Limited published literature reported that zolpidem is excreted in human milk and lacks information on its effects on milk production. There are reports of excessive sedation in infants exposed to zolpidem through breast milk. The health and developmental benefits of breastfeeding, the mother's clinical requirement for zolpidem, and any potential adverse reactions on the breastfed infant from zolpidem or the underlying maternal condition should be considered. Infants exposed to zolpidem through breast milk should be monitored for hypotonia, excess sedation, and respiratory depression. To minimize exposure to a breastfed infant, a lactating woman may temporarily interrupt breastfeeding and discard breast milk during treatment and for 23 hours (approximately&#x000a0;5 elimination half-lives) after zolpidem intake.<xref ref-type="bibr" rid="article-31475.r13">[13]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Pediatric patients should not be given zolpidem as its effectiveness has not been found yet. In addition, the research found that hallucinations occur in a small percentage of pediatric patients who received zolpidem.<xref ref-type="bibr" rid="article-31475.r14">[14]</xref></p>
        <p><bold>Older&#x000a0;patients: </bold>According to the American Geriatrics Society (AGS) 2023 Beers Criteria, nonbenzodiazepine receptor agonist hypnotics like zolpidem and benzodiazepines (BZDs) increase the risk of delirium, fractures, emergency room visits, motor vehicle accidents, and hospitalizations. Clinicians should avoid their use if possible.<xref ref-type="bibr" rid="article-31475.r15">[15]</xref>&#x000a0;According to FDA-approved product labeling, the dose should be reduced to 5 mg as serum concentrations are typically higher than in young adults.</p>
      </sec>
      <sec id="article-31475.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of zolpidem include anaphylaxis, changes in behavior, withdrawal, and central nervous system (CNS) depression. In rare situations, patients have reported tongue, larynx, or glottis swelling in the form of angioedema. Also, patients have reported&#x000a0;shortness of breath, airway closure, nausea, and vomiting. If&#x000a0;these events are reported, do not use zolpidem. Patients who experience closure in the throat, glottis, or larynx should be sent to the emergency&#x000a0;department.<xref ref-type="bibr" rid="article-31475.r16">[16]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Alcohol and CNS depressants:&#x000a0;Concurrent use of CNS depressants or alcohol with zolpidem may result in additive impairment of psychomotor performance and an increased risk of CNS depression. Due to potential additive effects, adjustments in the dosage of zolpidem and other concomitant CNS depressants may be necessary. For the 5 mg dose of zolpidem immediate-release, consider employing an alternative immediate-release product. Avoid combining zolpidem with other sedative-hypnotics at bedtime or during the night.</p>
        <p>Opioids:&#x000a0;Concurrent administration of zolpidem and opioids may elevate the risk of respiratory depression. Restrict the dosage and duration of simultaneous use of zolpidem and opioids; monitor for respiratory depression.&#x000a0;</p>
        <p>Imipramine and chlorpromazine:&#x000a0;Concurrent use of imipramine or chlorpromazine with zolpidem may produce an additive effect, decreasing alertness and psychomotor performance. In patients who are prescribed opioids, concurrent use of Z-drugs (eg, zolpidem) significantly raises the risk of overdose, even after accounting for confounding factors. This finding is particularly significant given the widespread use of Z-drugs among patients treated with opioids.<xref ref-type="bibr" rid="article-31475.r17">[17]</xref></p>
        <p>Sertraline:&#x000a0;Concurrent administration of zolpidem and sertraline increases exposure to zolpidem. Consider using another immediate-release product with a lower zolpidem dose (5 mg).</p>
        <p>CYP3A4 inducers:&#x000a0;Simultaneous zolpidem use with CYP3A4 inducers like rifampin may decrease zolpidem exposure, impacting its metabolism. St. John's Wort induces hepatic CYP enzymes, including CYP3A4 and CYP2B6. This accelerates the metabolism of zolpidem, potentially reducing its effectiveness.<xref ref-type="bibr" rid="article-31475.r18">[18]</xref></p>
        <p>CYP3A4 inhibitors: Simultaneous use of CYP3A4 inhibitors increases zolpidem exposure. Consider using another immediate-release product with a lower zolpidem dose. Additionally, clinicians should be aware that ciprofloxacin (a strong inhibitor of CYP1A2, a moderate inhibitor of CYP3A4) and fluvoxamine (a strong inhibitor of CYP1A2, a weak inhibitor of CYP2C9 and CYP3A4) can inhibit the metabolism of zolpidem, increasing the exposure to zolpidem.<xref ref-type="bibr" rid="article-31475.r19">[19]</xref></p>
      </sec>
      <sec id="article-31475.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Zolpidem is contraindicated in patients with a known allergy to the drug or inactive ingredients in the formulation. According to updated labeling, zolpidem is also contraindicated in patients with a history of complex sleep behaviors following its administration.&#x000a0;</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Complex sleep behaviors can occur after using zolpidem, such as sleep-driving, sleep-walking, and engaging in activities while not fully awake. These actions can lead to serious harm to the individual or others and, in some cases, be fatal. Additionally, other complex behaviors like making phone calls, engaging in sexual activity, or preparing and consuming food have been reported. Patients typically have no recollection of these events. Postmarketing data indicates that complex sleep behaviors can manifest with zolpidem tablets alone, even when taken at recommended doses, regardless of whether alcohol or other central nervous system (CNS) depressants are used concurrently. If a patient/caregiver reports a complex sleep behavior, it is crucial to discontinue zolpidem immediately.<xref ref-type="bibr" rid="article-31475.r20">[20]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Changes in behavior and abnormal thinking have been reported after zolpidem administration. In addition, patients have&#x000a0;demonstrated aggressiveness and extroversion uncommon for the person's usual behavior. Patients with alcohol or drug toxicities have experienced auditory and visual hallucinations associated with strange behavior and agitation. Consumption of alcohol or any other CNS depressant increased these events as they enhance sedation when combined. In these cases, the drug needs to be discontinued. Patients who are depressed should also not take zolpidem as it worsens depression and suicidal ideations and actions.<xref ref-type="bibr" rid="article-31475.r21">[21]</xref></p>
        <p>Caution should be used in patients taking drugs that affect drug metabolism via cytochrome P450. Consider giving a lower zolpidem dosage, as patients have shown to enhance sedative effects. In addition, patients taking imipramine and chlorpromazine should avoid using zolpidem. When combined, these medications cause decreased alertness and psychomotor performance.<xref ref-type="bibr" rid="article-31475.r22">[22]</xref></p>
        <p>Worsening of depression or suicidal ideation may occur with zolpidem therapy. Therefore, clinicians should prescribe the least amount of tablets possible to avoid intentional zolpidem overdose. Consider&#x000a0;the risk of respiratory depression before prescribing zolpidem in patients with compromised respiratory function. Withdrawal symptoms may occur if the zolpidem dose is tapered off rapidly or discontinued. Therefore, it is recommended to taper off slowly to avoid unnecessary withdrawal and adverse reactions in chronic zolpidem users.<xref ref-type="bibr" rid="article-31475.r23">[23]</xref></p>
      </sec>
      <sec id="article-31475.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The drug elimination half-life for 5 mg of zolpidem was found to be 2.6 hours. Respectively, the elimination for patients given 10 mg of zolpidem is 2.5 hours, ranging between 1.4 to 3.8 hours. Zolpidem&#x000a0;demonstrates a linear kinetics pattern when the dose range is between 5 mg and 20 mg. The drug was also found to be mostly&#x000a0;bound to protein and remained unchanged in concentration, subsequently extracted through the renal system.<xref ref-type="bibr" rid="article-31475.r24">[24]</xref></p>
        <p>This drug has a high potential for overuse and daily dependence. Patients with a few weeks of drug use have a low behavioral dependency on zolpidem. Patients who used zolpidem in higher single doses or had a history of drug abuse should be monitored carefully when using zolpidem or any other hypnotic.&#x000a0;Patients experience anterograde amnesia after drug administration if plasma concentrations are high during the stimulus. This is attributed to either inattention or consolidation of the memory process.<xref ref-type="bibr" rid="article-31475.r25">[25]</xref></p>
      </sec>
      <sec id="article-31475.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Drug overdose with zolpidem involves CNS depression, cognitive impairments leading to drowsiness or coma, cardiovascular and respiratory depression, and other fatalities. The acute toxicity of zolpidem is less in severity than other short-acting benzodiazepines like triazolam and midazolam. However, in combined intoxication with other CNS depressant drugs, zolpidem can induce coma in patients even with a low concentration. Single-drug poisoning is benign and should not require therapeutic intervention.&#x000a0;</p>
        <p>In cases of zolpidem overdose, gastric lavage should be considered within the first hour of ingestion to optimize its benefits. This procedure is most appropriate for conscious patients with a functional gag reflex, as it minimizes the risk of aspiration. Patients can also benefit from the administration of flumazenil and intravenous fluids&#x000a0;as well. Flumazenil is a known reversal agent for benzodiazepine toxicity. However, it can exacerbate other neurological symptoms, such as convulsions. In the event of drug toxicity, the patient's respiratory function, oxygen saturation, blood pressure, pulse, and other vitals should be monitored.<xref ref-type="bibr" rid="article-31475.r26">[26]</xref></p>
      </sec>
      <sec id="article-31475.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing insomnia and zolpidem use requires an interprofessional team approach of healthcare professionals, including pharmacists, therapists, nurses, and&#x000a0;clinicians (MD, DO, NP, PA). Prescribers should consider&#x000a0;the possibility of addiction and withdrawal symptoms when starting patients on zolpidem. Without proper management, significant drug-drug interactions may occur. For example, CNS depression is increased with the combination of opiates, benzodiazepines, antidepressants, or alcohol. Because the drug has the potential to cause dependence, it should not be prescribed for long periods, and the team should coordinate monitoring for dependency concerns. In addition, the patient should be counseled by nurses and pharmacists to avoid alcohol and other CNS depressants when taking zolpidem. Nurses can verify dose and therapy duration before zolpidem administration, and pharmacists can perform medication reconciliation to optimize the treatment with zolpidem and enhance patient outcomes.&#x000a0;An RCT investigated the impact of direct-to-patient education, with or without pharmacist consultation, on discontinuing Z-drugs (including eszopiclone, zolpidem, and zaleplon) in older adults. Despite recommendations discouraging their use, these medications are frequently prescribed to manage insomnia in this demographic. The study findings revealed that patients receiving education alone or in conjunction with a pharmacist consultation were significantly more likely to discontinue zolpidem than those receiving standard care.<xref ref-type="bibr" rid="article-31475.r27">[27]</xref></p>
      </sec>
      <sec id="article-31475.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31475&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31475">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31475/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31475">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31475.s11">
        <title>References</title>
        <ref id="article-31475.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kainth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhardwaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Maiwall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jamwal</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Shasthry</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Jindal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choudhary</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dhamija</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Sarin</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial.</article-title>
            <source>Clin Mol Hepatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-209</page-range>
            <pub-id pub-id-type="pmid">30856689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Van</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yosef</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conroy</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Zivin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Predictors of Long-Term and High-Dose Use of Zolpidem in Veterans.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2019</year>
            <month>Feb</month>
            <day>05</day>
            <volume>80</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30840786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjurstr&#x000f6;m</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Perioperative Pharmacological Sleep-Promotion and Pain Control: A Systematic Review.</article-title>
            <source>Pain Pract</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>552</fpage>
            <page-range>552-569</page-range>
            <pub-id pub-id-type="pmid">30762974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sateia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Buysse</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-349</page-range>
            <pub-id pub-id-type="pmid">27998379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hahm</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Paradoxical Motor and Cognitive Function Recovery in Response to Zolpidem in a Patient with Hypoxic-ischemic Brain Injury: A Case Report.</article-title>
            <source>Clin Psychopharmacol Neurosci</source>
            <year>2019</year>
            <month>Aug</month>
            <day>31</day>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>453</fpage>
            <page-range>453-457</page-range>
            <pub-id pub-id-type="pmid">31352715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rudolph</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Knutson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hentschke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Antkowiak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Zolpidem Activation of Alpha 1-Containing GABA<sub>A</sub> Receptors Selectively Inhibits High Frequency Action Potential Firing of Cortical Neurons.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1523</fpage>
            <pub-id pub-id-type="pmid">30687091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nigam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Camacho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The effect of nonbenzodiazepines sedative hypnotics on apnea-hypopnea index: A meta-analysis.</article-title>
            <source>Ann Thorac Med</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-55</page-range>
            <pub-id pub-id-type="pmid">30745935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capiau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huys</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van Poelgeest</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van der Velde</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Petrovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>A</given-names>
              </name>
              <collab>EuGMS Task, Finish Group on FRIDs</collab>
            </person-group>
            <article-title>Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review.</article-title>
            <source>Eur Geriatr Med</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>697</fpage>
            <page-range>697-708</page-range>
            <pub-id pub-id-type="pmid">36576689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Sep</month>
            <day>27</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>19150</fpage>
            <pub-id pub-id-type="pmid">34580385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pergolizzi</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raffa</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Nalamachu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness.</article-title>
            <source>Sleep Disord</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>527109</fpage>
            <pub-id pub-id-type="pmid">24649369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <article-title>Expanded table: Some oral hypnotics for chronic insomnia.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2018</year>
            <month>May</month>
            <day>07</day>
            <volume>60</volume>
            <issue>1546</issue>
            <fpage>e209</fpage>
            <page-range>e209-e213</page-range>
            <pub-id pub-id-type="pmid">30625124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juric</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Newport</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Galanti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stowe</surname>
                <given-names>ZN</given-names>
              </name>
            </person-group>
            <article-title>Zolpidem (Ambien) in pregnancy: placental passage and outcome.</article-title>
            <source>Arch Womens Ment Health</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>441</fpage>
            <page-range>441-6</page-range>
            <pub-id pub-id-type="pmid">19657707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Zolpidem</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonagh</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic Treatments for Sleep Disorders in Children: A Systematic Review.</article-title>
            <source>J Child Neurol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>237</fpage>
            <page-range>237-247</page-range>
            <pub-id pub-id-type="pmid">30674203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zammit</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparative tolerability of newer agents for insomnia.</article-title>
            <source>Drug Saf</source>
            <year>2009</year>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>735</fpage>
            <page-range>735-48</page-range>
            <pub-id pub-id-type="pmid">19670914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szmulewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huybrechts</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>The Risk of Overdose With Concomitant Use of Z-Drugs and Prescription Opioids: A Population-Based Cohort Study.</article-title>
            <source>Am J Psychiatry</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>178</volume>
            <issue>7</issue>
            <fpage>643</fpage>
            <page-range>643-650</page-range>
            <pub-id pub-id-type="pmid">33900810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hojo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Echizenya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohkubo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Drug interaction between St John's wort and zolpidem in healthy subjects.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>711</fpage>
            <page-range>711-5</page-range>
            <pub-id pub-id-type="pmid">21058968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlase</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Popa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muntean</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leucu&#x00163;a</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers.</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>3-4</issue>
            <fpage>83</fpage>
            <page-range>83-7</page-range>
            <pub-id pub-id-type="pmid">21302033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mittal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Zolpidem for Insomnia: A Double-Edged Sword. A Systematic Literature Review on Zolpidem-Induced Complex Sleep Behaviors.</article-title>
            <source>Indian J Psychol Med</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-381</page-range>
            <pub-id pub-id-type="pmid">34584301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for chronic insomnia.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>60</volume>
            <issue>1562</issue>
            <fpage>201</fpage>
            <page-range>201-205</page-range>
            <pub-id pub-id-type="pmid">30625122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hesse</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>von Moltke</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Clinically important drug interactions with zopiclone, zolpidem and zaleplon.</article-title>
            <source>CNS Drugs</source>
            <year>2003</year>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>513</fpage>
            <page-range>513-32</page-range>
            <pub-id pub-id-type="pmid">12751920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghaffar</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Prejean</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gremillion</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cogburn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chami</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Zolpidem: Efficacy and Side Effects for Insomnia.</article-title>
            <source>Health Psychol Res</source>
            <year>2021</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>24927</fpage>
            <pub-id pub-id-type="pmid">34746488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salv&#x000e0;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>142</fpage>
            <page-range>142-53</page-range>
            <pub-id pub-id-type="pmid">8521677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YB</given-names>
              </name>
            </person-group>
            <article-title>Compulsive activity and anterograde amnesia after zolpidem use.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2007</year>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-81</page-range>
            <pub-id pub-id-type="pmid">17364638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geulayov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferrey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bankhead</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gunnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hawton</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Relative toxicity of benzodiazepines and hypnotics commonly used for self-poisoning: An epidemiological study of fatal toxicity and case fatality.</article-title>
            <source>J Psychopharmacol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>654</fpage>
            <page-range>654-662</page-range>
            <pub-id pub-id-type="pmid">29442611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31475.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuntz</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kouch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Christian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Patient Education and Pharmacist Consultation Influence on Nonbenzodiazepine Sedative Medication Deprescribing Success for Older Adults.</article-title>
            <source>Perm J</source>
            <year>2019</year>
            <volume>23</volume>
            <fpage>18</fpage>
            <page-range>18-161</page-range>
            <pub-id pub-id-type="pmid">30624198</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
